SynthesisEuropean journal of epidemiology2010
Can statin therapy reduce the risk of melanoma? A meta-analysis of randomized controlled trials.
Synthesis in European journal of epidemiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 6 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Statins and the risk of colorectal cancer: an updated systematic review and meta-analysis of 40 studies.World journal of gastroenterology · 2014Pooled it
- Statin use is not associated with reduced risk of skin cancer: a meta-analysis.British journal of cancer · 2014Pooled it
- Potential increased risk of cancer from commonly used medications: an umbrella review of meta-analyses.Annals of oncology : official journal of the European Society for Medical Oncology · 2014Pooled it
- Statins are associated with reduced risk of gastric cancer: a meta-analysis.European journal of clinical pharmacology · 2013Pooled it
- Statins and the risk of lung cancer: a meta-analysis.PloS one · 2013Pooled it
- Use of fibrates and cancer risk: a systematic review and meta-analysis of 17 long-term randomized placebo-controlled trials.PloS one · 2012Pooled it
- A randomized, double-blind, placebo-controlled phase II clinical trial of lovastatin for various endpoints of melanoma pathobiology.Cancer prevention research (Philadelphia, Pa.) · 2014Trial
- Association of lipid-lowering drug targets with risk of cutaneous melanoma: a mendelian randomization study.BMC cancer · 2024Article
- Epigenetic suppression of PGC1α (PPARGC1A) causes collateral sensitivity to HMGCR-inhibitors within BRAF-treatment resistant melanomas.Nature communications · 2023Article
- Ulcerated Cutaneous Melanoma: A Review of the Clinical, Histologic, and Molecular Features Associated with a Clinically Aggressive Histologic Phenotype.Clinical, cosmetic and investigational dermatology · 2022Review
- Computational Drug Repositioning Identifies Statins as Modifiers of Prognostic Genetic Expression Signatures and Metastatic Behavior in Melanoma.The Journal of investigative dermatology · 2021Article
- Review
- Effect of Statin on Cancer Incidence: An Umbrella Systematic Review and Meta-Analysis.Journal of clinical medicine · 2019Article
- Review
- Statin use and endometrial cancer risk: a meta-analysis.Oncotarget · 2017Article
- Melanoma Chemoprevention: Current Status and Future Prospects.Photochemistry and photobiology · 2017Review
- Anti-proliferative and cytotoxic activity of rosuvastatin against melanoma cells.Postepy dermatologii i alergologii · 2016Article
- Tocilizumab unmasks a stage-dependent interleukin-6 component in statin-induced apoptosis of metastatic melanoma cells.Melanoma research · 2015Article
- Autocrine secretion of 15d-PGJ2 mediates simvastatin-induced apoptotic burst in human metastatic melanoma cells.British journal of pharmacology · 2014Article
- Statin use and its effect on all-cause mortality of melanoma patients: a population-based Dutch cohort study.Cancer medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A growing body of literature suggests that statins may have a chemopreventive potential against melanoma through pleiotropic anti-inflammatory, immunomodulatory, and antiangiogenesis mechanisms. Our aim was to examine this association through a detailed meta-analysis of randomized controlled trials (RCTs). A comprehensive search for trials published up to June 2009 was performed, reviews of each study were conducted and data were abstracted. Prior to meta-analysis, the studies were evaluated for publication bias and heterogeneity. Pooled relative risk estimates (RR) and 95% confidence intervals (CIs) were calculated using the fixed- and the random-effects models. Subgroup and sensitivity analyses were also conducted. Sixteen RCTs of statins for cardiovascular outcomes, involving 62,568 individuals with a mean age of 60 years and an average follow-up of nearly 4.7 years, contributed to the analysis. We found no evidence of publication bias (P = 0.47) or heterogeneity among the studies (P = 0.25). Statin use did not significantly affect the risk of developing melanoma assuming either a fixed- (RR = 0.92, 95% CI: 0.67-1.26), or a random-effects model (RR = 0.92, 95% CI: 0.62-1.36). This neutral effect was further supported by the results of subgroup and sensitivity analyses. Our findings do not support a protective effect of statins against melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.